Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Annexon (Nasdaq: ANNX), a biopharmaceutical company focused on classical complement-mediated neuroinflammatory diseases, has granted stock options to a new non-executive employee. The inducement grant was approved on August 11, 2025, under the company's 2022 Employment Inducement Award Plan and Nasdaq Listing Rule 5635(c)(4).

The grant consists of options to purchase 60,000 shares of Annexon common stock at an exercise price of $2.44 per share. The options have a ten-year term and vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years.

News Market Reaction

-6.81% 1.7x vol

5 alerts

-6.81% News Effect

-16.9% Trough in 29 hr 31 min

-$21M Valuation Impact

$282M Market Cap

1.7x Rel. Volume

On the day this news was published, ANNX declined 6.81%, reflecting a notable negative market reaction. Argus tracked a trough of -16.9% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $21M from the company's valuation, bringing the market cap to $282M at that time. Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

BRISBANE, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on August 11, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).

The new non-executive employee received an option to purchase 60,000 shares of Annexon common stock. The option carries a ten-year term and an exercise price per share equal to $2.44, which was the closing price of Annexon’s common stock on August 15, 2025, the date of grant, and vests over 4 years, with 25% of the shares underlying the options vesting on the first anniversary of the grant date and an additional 1/48th of the shares vesting monthly thereafter, subject to continued service through the applicable vesting dates.

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is developing therapeutics that stop classical complement-driven neuroinflammation as first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of classical complement’s potent inflammatory pathway that when misdirected can lead to tissue damage and loss in a host of diseases. By targeting C1q, our immunotherapies are designed to stop this neuroinflammatory cascade before it starts. Our pipeline spans three diverse therapeutic areas – autoimmunity, neurodegeneration and ophthalmology – and includes targeted investigational drug candidates designed to address the unmet needs of nearly 10 million people worldwide. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.

Investor Contact:

Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com

FAQ

What stock options did Annexon (ANNX) grant to its new employee in August 2025?

Annexon granted options to purchase 60,000 shares of common stock at an exercise price of $2.44 per share to a new non-executive employee.

What is the vesting schedule for Annexon's (ANNX) August 2025 employee stock options?

The options vest over 4 years, with 25% vesting after the first year and 1/48th vesting monthly thereafter, subject to continued employment.

What is the exercise price of Annexon's (ANNX) August 2025 inducement grant?

The exercise price is $2.44 per share, which was Annexon's closing stock price on August 15, 2025.

When do the Annexon (ANNX) August 2025 employee stock options expire?

The stock options carry a ten-year term from the date of grant.